Risk factor for VTE in cancer patients
| Risk factors . |
|---|
| Patient-related |
| Advanced age |
| Comorbidities |
| Immobilization or hospitalization |
| Previous VTE |
| Hereditary thrombophilia |
| Tumor-related |
| Tumor type |
| • Very high risk: gastric, pancreas, brain |
| • High risk: lung, hematologic, gynecologic, renal, bladder |
| Cancer stage |
| Histological tumor grade |
| Localized tumor compression |
| Treatment-related |
| Chemotherapy (eg cisplatin-based, antiangiogenesis agents) |
| Hormonal therapy |
| Red blood cell transfusions and erythropoiesis-stimulating agents |
| Surgery |
| Radiotherapy |
| Central venous catheters |
| Risk factors . |
|---|
| Patient-related |
| Advanced age |
| Comorbidities |
| Immobilization or hospitalization |
| Previous VTE |
| Hereditary thrombophilia |
| Tumor-related |
| Tumor type |
| • Very high risk: gastric, pancreas, brain |
| • High risk: lung, hematologic, gynecologic, renal, bladder |
| Cancer stage |
| Histological tumor grade |
| Localized tumor compression |
| Treatment-related |
| Chemotherapy (eg cisplatin-based, antiangiogenesis agents) |
| Hormonal therapy |
| Red blood cell transfusions and erythropoiesis-stimulating agents |
| Surgery |
| Radiotherapy |
| Central venous catheters |
Adapted from Ay et al.55 Shown are risk factors for VTE that may be considered in the decision to stop or continue anticoagulation after an initial 3- to 6-month treatment of VTE in cancer patients.